NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...

Lantheus is growing revenue and earnings at an above-average pace. The strong pipeline of Phase 3 compounds can sustain growth for multiple years. The attractive low valuation and strong growth makes ...

BEDFORD, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow ® disease ...

Lantheus Holdings (NASDAQ: LNTH) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic ...

Lantheus imaging products include the echocardiography contrast agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, ABLAVAR ® (gadofosveset trisodium), a first-in-class ...

(RTTNews) - Lantheus Holdings, Inc. (LNTH) announced the FDA has approved the supplemental new drug application for DEFINITY as an ultrasound enhancing agent for use in pediatric patients with ...

BILLERICA — A local radiopharmaceutical company celebrated the completion of a $12 million renovation to Building 110 on its Billerica campus Thursday morning as it continues to increase production of ...

Lantheus Holdings, Inc. LNTH has been gaining from its focus on pipeline development. The optimism, led by a solid first-quarter 2024 performance and strength in radiopharmaceuticals, is expected to ...

Lantheus’ third quarter was marked by a negative market reaction, as investors responded to lower operating margins and significant leadership changes despite revenue exceeding Wall Street’s ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global ...